Kornimate/medical-research-clean huggingface dataset:
prospective study of lymphoproliferative diseases

Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma

Summary: this study will help researchers learn more about non-hodgkin's lymphoma and hodgkin's lymphoma and how it is treated in kenya. researchers want to see if having certain viruses like epstein barr virus (ebv), human immunodeficiency virus (hiv), and kaposi's sarcoma herpes virus (kshv) affects lymphoma. patients in kenya who agree to be in this study will let the resesarchers look at their medical record, follow their normal cancer care, and have blood drawn to look at different proteins and viruses. researchers would also like to look at part of the original tumor that was taken out of each patient. some of these samples will be stored at kenyatta national hospital and research will be done on them later. this study does not involve any change in treatment, but only allows the study team to follow how a patient in kenya with lymphoma is treated.

comprehensive prospective cohort study of lymphoproliferative diseases in nairobi, kenya.

Eligibility criteria:
inclusion criteria: * all subjects regardless of age, sex or hiv serostatus must have biopsy-proven non-hodgkin's (nhl), including primary effusion lymphoma, hodgkin's lymphoma (hd) or other lymphoproliferative disorder (e.g., castleman's disease) with measurable or evaluable stage i through iv disease. \[note: lymphomas will be categorized on the basis of current who classification scheme, but it is recognized that initial pathological categorization at time of study enrollment will more than likely be classified or graded as low-, intermediate-, or high-grade lymphoma by working formulation criteria. this is the current standard of practice in kenya.\] * all subjects must receive some form of systemic chemotherapy. subjects not receiving chemotherapy of any kind are not eligible. subjects must not have had any prior chemotherapy for lymphoma. * subjects may have received prior radiotherapy for localized stage i or stage ii disease that is clearly documented to have progressed beyond initial radiotherapy ports. * all subjects must give written informed consent to participate on study. in kenya, a child is considered \ 11 years old assent should be documented using the irb approved assent form. exclusion criteria: * subjects who do not fulfill the criteria as listed in sections 3.1.1 through 3.1.4 are ineligible. * subjects who received prior chemotherapy (i.e., first-line treatment) or are not receiving any chemotherapy for their non-hodgkin's (nhl) or hodgkin's lymphoma (hd) are ineligible.

Keywords: non-hodgkin's lymphoma hodgkin's lymphoma kenya epstein barr virus (ebv) human immunodeficiency virus (hiv) kaposi's sarcoma herpes virus (kshv)
a clinical follow-up study of heart failure patients.

Conditions: Heart Failure

Summary: heart failure (hf), a current worldwide pandemic with an unacceptable high level of morbidity and mortality, brings an enormous medical and societal burden. chronic hf is characterized by progressive alteration of cardiac structure and function. but the molecular mechanism of these alterations is still not well-established and needs to be discussed further. hf is a highly heterogeneous disease that can be caused by a multiple of diseases. dilated cardiomyopathy (dcm) and ischemic cardiomyopathy (icm) are the main causes of this syndrome. although hf is the common manifestation of dcm and icm, the etiology and pathogenesis are different. understanding the different pathophysiological mechanisms will contribute to the prevention and individualized therapy of heart failure. therefore, this study aims to observation the different characteristics of the molecular biology and clinical courses in dcm and icm patients.


Eligibility criteria:
inclusion criteria: * lvef≤ 55% * enlarged left ventricular end-diastolic dimension * icm group: with history of mi or revascularization; ≥ 75% stenosis of lm or proximal lad; ≥ 75% stenosis of two or more epicardial vessels. * symptomatic heart failure exclusion criteria: * known malignant tumour diseases * pregnancy or lactation period； * investigators think not suitable to participate in this trial.
ketone administration during inactivity and retraining

Conditions: Exercise; Healthy Male/Female Subjects

Summary: the aim of this study is to investigate the effect of oral ketone administration during inactivity-induced muscle atrophy and retraining-induced regeneration. potential changes in muscle function (cycling performance, knee-extension force and power, jump height) and mass, blood flow and the muscular extracellular matrix will be the main focus. in this context, the dominant leg of the participants (n=24) will be immobilized with a brace for 2 weeks and subsequently retrained in a 4-week progressive resistance exercise training program to stimulate muscle regeneration. during the immobilization and rehabilitation period, participants receive either ketone ester (ke) or placebo (con). 4 experimental sessions are performed during this time frame in order to evaluate the effects of the trial.


Eligibility criteria:
inclusion criteria: * recreational sports participation, including general fitness training, between 2 and 5 hours max per week * good health status confirmed by a medical screening * body mass index between 18 and 25 exclusion criteria: * any kind of injury/pathology that is a contra-indication to perform resistance exercise * intake of any medication or nutritional supplement that could impact muscle protein synthesis during the period of the study * intake of any whey protein, casein or branched-chain amino acid supplement or anti-inflammatory drug from 1 month prior to the start of the study * blood donation within 3 months prior to the start of the study * smoking * pregnant * more than 3 alcoholic beverages per day * current participation in another research trial * any other argument to believe that the subject is unlikely to successfully complete the full study protocol * adherence to a high-fat, low-carbohydrate ketogenic diet (less than 20% of energy intake derived from carbohydrates) * (cow's) milk protein allergy

Keywords: ketone inactivity-induced muscle atrophy retraining-induced regeneration
multimodal, task-aware movement assessment and control using functional electrical stimulation

Conditions: Post-stroke

Summary: the study aims to investigate the relationship between post-stroke adults' movement patterns and disability levels. utilizing the functional electrical stimulation (fes) system for individualized dorsiflexor and plantar flexor assistance during gait cycles. the investigators will analyze the cycles with and without the fes system. initially, the context-aware motion assessment and neuroprosthetic control in a clinic will transition to in-home settings as the study progresses, broadening its application for safe and effective use at home.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * capacity to consent * post-stroke community-dwelling adults * ability to follow 3-step commands exclusion criteria: * undomiciled * active substance use disorder * active psychosis * domestic violence or neglect * inability to communicate with investigators * other comorbidities that prevent full participation in the research

Keywords: functional electrical stimulation
comparison of immuno, reacto and safety of recombinant hepatitis b vaccine with or without mpl in healthy older adults

Conditions: Hepatitis B

Summary: in the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis b vaccines with and without mpl will be evaluated in older healthy subjects

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham

Eligibility criteria:
inclusion criteria: * healthy male or female subjects between 50 and 70 years old. * written informed consent will have been obtained from the subjects. * good physical condition as established by physical examination and history taking at the time of entry exclusion criteria: * positive titres for anti hepatitis antibodies * any vaccination against hepatitis b in the past. * any previous administration of mpl * elevated serum liver enzymes at two subsequent determinations 14 days apart. * history of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. * axillary temperature \> 37.5°c at the time of injection. * any acute disease at the moment of entry. * chronic alcohol consumption. * any treatment with immunosuppressive or immunostimulant therapy. * any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study. * history of allergic disease likely to be stimulated by any component of the vaccine. * administration of any other vaccine(s) or any immunoglobulin during the study period. * simultaneous participation in any other clinical trial.

Keywords: hepatitis b engerix™-b recombinant hepatitis b vaccine
diclofenac for submassive pe

Conditions: Pulmonary Embolism

Summary: the primary objective is to demonstrate the clinical benefits of diclofenac (added to standard anticoagulant therapy) over placebo in normotensive patients with acute symptomatic pulmonary embolism and right ventricular dysfunction. the secondary objective is to assess the safety after administration of diclofenac in normotensive patients with acute symptomatic pulmonary embolism and right ventricular dysfunction.


Eligibility criteria:
inclusion criteria: 1. acute symptomatic pe confirmed by multidetector ct angiography, a high-probability v/q scan, or by the presence of deep vein thrombosis confirmed by lower limb ultrasound testing in patients with nonconclusive v/q scan; 2. first symptoms occurring ten days or less before randomization; 3. haemodynamic stability (systolic blood pressure \> 100 mm hg, no need of inotropic support, pulmonary resuscitation, intubation or thrombolytic treatment); 4. right ventricular dysfunction assessed by transthoracic echocardiography within the first 12 hours after diagnosis of pe; 5. signed informed consent. exclusion criteria: 1. previous diagnosis of chronic thromboembolic pulmonary hypertension; 2. active bleeding, or clinically relevant bleeding in the previous month before diagnosis of pe; 3. peptic ulcer; 4. major surgery, or severe trauma in the previous month before diagnosis of pe; 5. indication for chronic anticoagulation; 6. pregnancy or breast feeding; 7. renal insufficiency (serum creatinine \> 2 mg/dl) or severe hepatic impairment; 8. hypersensitivity to diclofenac, sodium metabisulfite, or acetylsalicylic acid; 9. bronchial asthma; 10. severe congestive heart failure; 11. inflammatory bowel disease.

Keywords: pulmonary embolism right ventricular dysfunction prognosis inflammation
immune ablation and stem cell support for crohn's disease

Conditions: Crohn Disease

Summary: the investigators anticipate that this study will also form the basis to clarify further the role of the immune system in crohn's disease.

this study is designed to ablate an aberrant immune system and then, similar to the use of marrow transplants for immunodeficient patients, reconstitute a new immune system with lymphocyte depleted stem cells. subsequent disease activity will be followed by (1) crohn's disease activity index (cdai), (2) quality of life instrument (ibdq), (3) type and amount of therapy for cd, and (4) flow cytometry of peripheral blood lymphocyte subsets. in addition, the subjects will undergo periodic absorption function testing, to assess small intestinal function. we anticipate that this study will also form the basis to clarify further the role of the immune system in crohn's disease.

Eligibility criteria:
inclusion criteria: * less than physiologic age 60 at time of pretransplant evaluation. * an established clinical diagnosis of severe cd that has failed therapy with prednisone, azathioprine, 5 asa products and metronidazole, and has failed to have a sustained decrement of 70 points in the cdai after one course of anti-tnf alpha, infliximad. the patient is being considered for therapy with cyclosporin a (csa) or surgical resection. the cdai (appendix a) is 250-400. * pre-study peripheral blood counts must include a platelet count greater than 100,000/ul and an absolute neutrophil count greater than 1500/ul. * stem cell harvest greater than 1.4 x 106 cd34 cells/kg after cd34+ selection (to continue to transplant.) exclusion criteria: * hiv positive * history of coronary artery disease, or congestive heart failure. * uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy * prior history of malignancy except localized basal cell or squamous skin cancer. other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage i breast cancer will be considered on an individual basis. * positive pregnancy test, lactation, inability or unwillingness to pursue effective means of birth control, failure to accept or comprehend irreversible sterility as a side effect of therapy. * psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible. * fev i/fvc \< 50% of predicted, dlco \< 50% of predicted. * resting lvef \< 40% * bilirubin \> 2.0 mg/dl, transferase (ast) \> 2x upper limit of normal, unless the abnormalities are secondary to crohn's disease. * serum creatinine \> 2.0 mg/dl. * platelet count less than 100,000/ul, anc less than 1500/ul. * patients presenting with intestinal perforation or toxic megacolon, or a suppurative problem that will require urgent surgery. in addition, the patient may not have any active infection. the presence of intestinal stomas does not exclude the patient from study.
fapi and fdg pet/mri in diagnosis and therapy prediction of bladder cancer

Conditions: Urinary Bladder Neoplasms

Summary: the aim of this trial is to investigate the value of fapi pet/mri, fdg pet/mri and mri in diagnosing mibc and predicting the efficacy of neoadjuvant therapy for mibc patients, so as to guide the clinic to adjust the treatment plan in time and benefit mibc patients.

the mibc diagnostic study was a prospective trial. according to the inclusion and exclusion criteria, patients with suspected mibc were enrolled and underwent fapi pet/mri, fdg pet/mri and mri examination, and the imaging data and clinical laboratory and pathologic data were collected, and the postoperative pathological results were used as the gold standard to compare the accuracy of fapi pet/mri, fdg pet/mri and mri in diagnosing mibc. the mibc neoadjuvant therapy efficacy assessment study was a prospective trial. patients with mibc were enrolled according to the inclusion and exclusion criteria, the regimen was selected individually according to the patient's condition, and the indicators were followed up until the end of time or the occurrence of an endpoint event to obtain information on survival time. fapi pet/mri, fdg pet/mri and mri were performed once before the start of neoadjuvant therapy and once after the end of therapy, and after the end of neoadjuvant therapy, patients received transurethral cystectomy of bladder tumors or radical cystectomy according to the efficacy and condition, and the combination of the imaging data and the clinical laboratory and pathological data were used to compare fapi pet/mri, fdg pet/ mri and mri in the assessment of the efficacy of neoadjuvant therapy in mibc patients to guide clinical treatment options.

Eligibility criteria:
inclusion criteria: * inclusion criteria for mibc diagnostic studies 1. patients with suspected muscle-invasive bladder cancer; 2. completion of fapi pet/mri, fdg pet/mri and mri; 3. complete clinical laboratory and pathological data. * inclusion criteria for mibc neoadjuvant therapy efficacy evaluation study 1. patients diagnosed with muscle invasive bladder cancer; 2. completion of fapi pet/mri, fdg pet/mri, and mri before neoadjuvant therapy; 3. complete clinical laboratory and pathological data. exclusion criteria: * exclusion criteria for mibc diagnostic study 1. combined with other malignant tumors; 2. not receiving surgical treatment; 3. receiving neoadjuvant therapy before surgery; 4. previous allergy to contrast components or similar components; 5. serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities; 6. incomplete clinicopathological data * exclusion criteria of mibc neoadjuvant therapy efficacy evaluation study 1. combination of other malignant tumors; 2. fapi pet/mri, fdg pet/mri and mri were not completed after neoadjuvant therapy; 3. prior hypersensitivity to contrast components or similar components; 4. serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function; 5. incomplete clinicopathological data.

Keywords: neoadjuvant chemotherapy neoplasm staging
rapid detection of group b streptococcus (strep)-labor and delivery study

Conditions: Streptococcal Infections

Summary: the purpose of this study is to determine whether a rapid bedside diagnosis of group b strep (gbs) growing in the vagina and rectum can be performed with similar success to the routine culture in women who are in labor.

group b strep neonatal infections is one of the leading infections in newborns, most of which are acquired by vertical transmission at the time of childbirth. most cases can be prevented by identifying women who are colonized with gbs in the vaginal-rectal area and giving colonized women prophylactic antibiotics in labor. about 15-20% of women are colonized and nearly all of these women are asymptomatic. because it takes up to 48 hours to obtain culture results, it is currently recommended to perform cultures in the clinic about 5 weeks prior to their due date and then treat those with gbs when they come in for labor. there are several downsides to this strategy. all women who present with preterm labor are treated until culture results become available (overtreatment); women who go into labor while waiting for culture results are all treated (overtreatment); prior studies have shown 33% of women are positive at 35 weeks, but negative at birth (overtreatment) and 10% are negative at 35 weeks and positive at birth (undertreatment); lost or missing culture results (over- or undertreatment). using microfluidics and fluorescent pcr, a new test can identify gbs reliably in 30 to 45 minutes in vitro. this study proposes to evaluate the clinical performance (sensitivity, specificity, positive and negative predictive value) of the microfluidic rapid gbs technique in un-selected sequential women presenting to labor and delivery, comparing them to cultures taken at the same time and the 35-37 week cultures in these same women. we will also evaluate the identification of gbs before and after rupture of membranes (amniotomy) using both standard gbs culture and rapid pcr (handylab technology).

Eligibility criteria:
inclusion criteria: * women 18 years of age or older * mentally capable of giving informed consent * symptoms and signs at presentation related to possible labor or ruptured membranes (leakage of fluid, uterine contractions, pelvic pressure) * presentation for induction of labor irrespective of cause exclusion criteria: * inability to give informed consent * conditions where the time taken to obtain specimens are potentially harmful to one or one's baby (heavy bleeding, low fetal heart rate, preterm premature rupture of membranes) * use of any antibacterials within the previous 7 days

Keywords: streptococcus group b pregnancy
an open label study for participants with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the primary purpose of this study is to help answer if ly2127399 is safe and effective during long-term treatment in participants with rheumatoid arthritis. this study is comprised of 2 periods: period 1: unblinded treatment for up to 240 weeks for participants who enroll from study h9b-mc-bcdo (bcdo) (nct01202760) or study h9b-mc-bcdv (bcdv) (nct01202773) or up to 168 weeks for participants who enroll from study h9b-mc-bcdm (bcdm) (nct01198002). period 2: 48-week post-treatment follow-up

week 16 non-responders (nr) are participants with \<20% improvement from baseline in both tender and swollen joint counts when assessed at week 16 of studies bcdo, bcdv and bcdm.

Eligibility criteria:
inclusion criteria: * have completed 24 weeks of participation in study h9b-mc-bcdo or study h9b-mc-bcdv, or have completed 100 weeks of participation in study h9b-mc-bcdm * woman must not be pregnant, breastfeeding, or become pregnant during the study exclusion criteria: * current presence of a serious disorder or illness

Keywords: rheumatoid arthritis
self reported pain in women while undergoing treatment for non-metastatic breast cancer

Conditions: Breast

Summary: the overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.this study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. participation in this study will not affect your cancer treatment.

this study will measure pain using esas self-reported pain scores over the course of one week following each dose of pegfilgrastim (or biosimilar substitution). at the end of that week, blood will be drawn from each subject to directly measure the wbc/anc, which can then be compared to self-reported pain and evaluated for any correlation. finally, subjects will be divided into two groups by age: 45 years or younger, and over 45 to look for any differences in pain or wbc/anc measurements based on age.

Eligibility criteria:
inclusion criteria subject must meet all the following applicable inclusion criteria to participate in this study: 1. written informed consent and hipaa authorization for release of personal health information. note: hipaa authorization may be included in the informed consent or obtained separately. 2. age ≥ 18 years at the time of consent 3. female 4. histological or cytological confirmation of invasive breast cancer. 5. planned to undergo adjuvant or neoadjuvant chemotherapy treatment for invasive breast cancer and pegfilgrastim (or biosimilar substitution) treatment for neutropenic prophylaxis. 6. ability to read and understand the english and/or spanish language 7. as determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study exclusion criteria subjects meeting any of the criteria below may not participate in the study: 1. uncontrolled intercurrent illness/medical condition or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator 2. have previously received chemotherapy or radiation other than the first cycle of the planned adjuvant or neoadjuvant chemotherapy as indicated in inclusion #5 3. taking chronic narcotics, as determined by treating physician 4. diagnosis of distant metastatic breast cancer 5. diagnosis of a chronic pain syndrome (e.g. fibromyalgia, severe osteoarthritis, etc.) 6. a baseline esas pain score of greater than 8.